PL3139925T3 - Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu - Google Patents
Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchuInfo
- Publication number
- PL3139925T3 PL3139925T3 PL15724438T PL15724438T PL3139925T3 PL 3139925 T3 PL3139925 T3 PL 3139925T3 PL 15724438 T PL15724438 T PL 15724438T PL 15724438 T PL15724438 T PL 15724438T PL 3139925 T3 PL3139925 T3 PL 3139925T3
- Authority
- PL
- Poland
- Prior art keywords
- valbenazine
- hyperkinetic
- treatment
- motion disorders
- dosage scheme
- Prior art date
Links
- GEJDGVNQKABXKG-CFKGEZKQSA-N [(2r,3r,11br)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl] (2s)-2-amino-3-methylbutanoate Chemical compound C1CN2C[C@@H](CC(C)C)[C@H](OC(=O)[C@@H](N)C(C)C)C[C@@H]2C2=C1C=C(OC)C(OC)=C2 GEJDGVNQKABXKG-CFKGEZKQSA-N 0.000 title 1
- 230000001660 hyperkinetic effect Effects 0.000 title 1
- 229950006411 valbenazine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461989240P | 2014-05-06 | 2014-05-06 | |
| EP15724438.5A EP3139925B1 (en) | 2014-05-06 | 2015-05-06 | Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders |
| PCT/US2015/029519 WO2015171802A1 (en) | 2014-05-06 | 2015-05-06 | Vmat2 inhibitors for the treatment of hyperkinetic movement disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3139925T3 true PL3139925T3 (pl) | 2022-03-21 |
Family
ID=53264772
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15724438T PL3139925T3 (pl) | 2014-05-06 | 2015-05-06 | Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu |
| PL21178882.3T PL3936130T3 (pl) | 2014-05-06 | 2015-05-06 | Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21178882.3T PL3936130T3 (pl) | 2014-05-06 | 2015-05-06 | Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20170071932A1 (pl) |
| EP (3) | EP3936130B1 (pl) |
| JP (4) | JP6635945B2 (pl) |
| KR (5) | KR20200133003A (pl) |
| CN (3) | CN106456629A (pl) |
| AU (1) | AU2015256012B2 (pl) |
| CA (1) | CA2947736C (pl) |
| CY (1) | CY1125058T1 (pl) |
| DK (2) | DK3139925T3 (pl) |
| ES (2) | ES2976207T3 (pl) |
| FI (1) | FI3936130T3 (pl) |
| HR (2) | HRP20240459T1 (pl) |
| HU (2) | HUE066361T2 (pl) |
| IL (1) | IL248745B (pl) |
| LT (2) | LT3936130T (pl) |
| MX (1) | MX387625B (pl) |
| NZ (1) | NZ725826A (pl) |
| PL (2) | PL3139925T3 (pl) |
| PT (2) | PT3139925T (pl) |
| RS (2) | RS65359B1 (pl) |
| RU (1) | RU2753740C2 (pl) |
| SI (2) | SI3936130T1 (pl) |
| SM (2) | SMT202400199T1 (pl) |
| WO (1) | WO2015171802A1 (pl) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2972600T3 (es) | 2015-10-30 | 2024-06-13 | Neurocrine Biosciences Inc | Sales de diclorhidrato de valbenazina y polimorfos de las mismas |
| DK3394057T3 (da) | 2015-12-23 | 2022-04-11 | Neurocrine Biosciences Inc | Syntetisk fremgangsmåde til fremstilling af (S)-(2R,3R,11BR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11B-hexahydro-1H-pyrido[2,1,-A]isoquinolin-2-yl 2-amino-3-methylbutanoat-di(4-methylbenzensulfonat) |
| ES2811048T3 (es) * | 2016-06-29 | 2021-03-10 | Crystal Pharmaceutical Suzhou Co Ltd | Formas cristalinas de NBI-98854, método de preparación para las mismas y uso de las mismas |
| TW202515564A (zh) * | 2016-12-02 | 2025-04-16 | 美商紐羅克里生物科學有限公司 | 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途 |
| WO2018130345A1 (en) | 2017-01-10 | 2018-07-19 | Sandoz Ag | Crystalline valbenazine free base |
| JP7199359B2 (ja) | 2017-01-27 | 2023-01-05 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| US10954235B2 (en) | 2017-02-27 | 2021-03-23 | Sandoz Ag | Crystalline forms of valbenazine salts |
| WO2018164996A1 (en) * | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
| GB201705305D0 (en) * | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| US20190111035A1 (en) * | 2017-04-01 | 2019-04-18 | Adeptio Pharmaceuticals Limited | Pharmaceutical compositions |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| RU2771164C2 (ru) * | 2017-04-01 | 2022-04-27 | Адептио Фармасьютикалз Лимитед | (+)-альфа-дигидротетрабеназин для использования при лечении двигательного расстройства |
| WO2018178243A2 (en) * | 2017-04-01 | 2018-10-04 | Adeptio Pharmaceuticals Limited | Pharmaceutical compositions |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705303D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| WO2018200605A1 (en) * | 2017-04-26 | 2018-11-01 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
| BR112020005373A2 (pt) | 2017-09-21 | 2020-09-24 | Neurocrine Biosciences Inc. | formulação de valbenazina em alta dosagem e composições, métodos e kits relacionados com valbenazina |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| SG11202003194YA (en) * | 2017-10-10 | 2020-05-28 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| EP3706748A4 (en) * | 2017-11-08 | 2021-08-11 | Foresee Pharmaceuticals Co., Ltd. | ESTER OF DIHYDROTETRABENAZINE |
| US11339158B2 (en) | 2017-12-26 | 2022-05-24 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof |
| TWI832854B (zh) * | 2018-04-25 | 2024-02-21 | 美商神經治療股份有限公司 | 丁苯那嗪經皮輸送裝置 |
| GB201808464D0 (en) | 2018-05-23 | 2018-07-11 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compounds for use in treating huntington's disease |
| TW202011963A (zh) | 2018-06-14 | 2020-04-01 | 美商紐羅克里生物科學有限公司 | Vmat2抑制劑化合物、組合物及其相關方法 |
| MA53239A (fr) | 2018-08-15 | 2022-05-04 | Neurocrine Biosciences Inc | Procédés d'administration de certains inhibiteurs de vmat2 |
| EP3860599B1 (en) | 2018-10-04 | 2024-05-15 | Adeptio Pharmaceuticals Limited | (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders |
| JP2022531696A (ja) * | 2019-05-09 | 2022-07-08 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２阻害剤を投与するための方法 |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007317242B2 (en) * | 2006-11-08 | 2013-08-01 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto |
| WO2008060451A2 (en) * | 2006-11-09 | 2008-05-22 | New York University | Graded glass/zirconia/glass structures for damage resistant ceramic dental and orthopedic prostheses |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| US20110053866A1 (en) * | 2008-08-12 | 2011-03-03 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| US8524733B2 (en) | 2008-09-18 | 2013-09-03 | Auspex Pharmaceuticals | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| JP2013501810A (ja) * | 2009-08-12 | 2013-01-17 | ヴァリーント インターナショナル（バルバドス）エスアールエル | 医薬組成物 |
| WO2011153157A2 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| IN2015DN01662A (pl) * | 2012-09-18 | 2015-07-03 | Auspex Pharmaceuticals Inc | |
| CN113368110A (zh) * | 2014-02-07 | 2021-09-10 | 纽罗克里生物科学有限公司 | 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途 |
-
2015
- 2015-05-06 SI SI201532006T patent/SI3936130T1/sl unknown
- 2015-05-06 HR HRP20240459TT patent/HRP20240459T1/hr unknown
- 2015-05-06 AU AU2015256012A patent/AU2015256012B2/en active Active
- 2015-05-06 SM SM20240199T patent/SMT202400199T1/it unknown
- 2015-05-06 ES ES21178882T patent/ES2976207T3/es active Active
- 2015-05-06 RS RS20240380A patent/RS65359B1/sr unknown
- 2015-05-06 EP EP21178882.3A patent/EP3936130B1/en active Active
- 2015-05-06 PT PT157244385T patent/PT3139925T/pt unknown
- 2015-05-06 LT LTEP21178882.3T patent/LT3936130T/lt unknown
- 2015-05-06 HU HUE21178882A patent/HUE066361T2/hu unknown
- 2015-05-06 PT PT211788823T patent/PT3936130T/pt unknown
- 2015-05-06 CN CN201580023821.XA patent/CN106456629A/zh active Pending
- 2015-05-06 DK DK15724438.5T patent/DK3139925T3/da active
- 2015-05-06 MX MX2016014429A patent/MX387625B/es unknown
- 2015-05-06 US US15/309,108 patent/US20170071932A1/en not_active Abandoned
- 2015-05-06 PL PL15724438T patent/PL3139925T3/pl unknown
- 2015-05-06 KR KR1020207032879A patent/KR20200133003A/ko not_active Ceased
- 2015-05-06 EP EP15724438.5A patent/EP3139925B1/en active Active
- 2015-05-06 WO PCT/US2015/029519 patent/WO2015171802A1/en not_active Ceased
- 2015-05-06 KR KR1020257005033A patent/KR20250029267A/ko active Pending
- 2015-05-06 KR KR1020167033765A patent/KR20160147044A/ko not_active Ceased
- 2015-05-06 CN CN202011483135.XA patent/CN112741835A/zh active Pending
- 2015-05-06 PL PL21178882.3T patent/PL3936130T3/pl unknown
- 2015-05-06 HR HRP20220025TT patent/HRP20220025T1/hr unknown
- 2015-05-06 HU HUE15724438A patent/HUE057839T2/hu unknown
- 2015-05-06 EP EP24157482.1A patent/EP4389227A3/en not_active Withdrawn
- 2015-05-06 SM SM20220193T patent/SMT202200193T1/it unknown
- 2015-05-06 ES ES15724438T patent/ES2904526T3/es active Active
- 2015-05-06 KR KR1020247001490A patent/KR20240011255A/ko not_active Ceased
- 2015-05-06 LT LTEPPCT/US2015/029519T patent/LT3139925T/lt unknown
- 2015-05-06 SI SI201531799T patent/SI3139925T1/sl unknown
- 2015-05-06 IL IL248745A patent/IL248745B/en unknown
- 2015-05-06 RU RU2016147523A patent/RU2753740C2/ru active
- 2015-05-06 JP JP2016566238A patent/JP6635945B2/ja active Active
- 2015-05-06 FI FIEP21178882.3T patent/FI3936130T3/fi active
- 2015-05-06 CA CA2947736A patent/CA2947736C/en active Active
- 2015-05-06 DK DK21178882.3T patent/DK3936130T3/da active
- 2015-05-06 NZ NZ725826A patent/NZ725826A/en unknown
- 2015-05-06 CN CN202011483141.5A patent/CN112741836A/zh active Pending
- 2015-05-06 RS RS20220008A patent/RS62782B1/sr unknown
- 2015-05-06 KR KR1020227034399A patent/KR20220140647A/ko not_active Ceased
-
2019
- 2019-10-02 JP JP2019181949A patent/JP2019218407A/ja not_active Withdrawn
- 2019-12-03 US US16/701,339 patent/US20200101063A1/en not_active Abandoned
-
2020
- 2020-09-15 US US17/021,362 patent/US20210196702A1/en not_active Abandoned
-
2021
- 2021-09-22 JP JP2021153918A patent/JP2021191799A/ja not_active Withdrawn
-
2022
- 2022-02-07 CY CY20221100104T patent/CY1125058T1/el unknown
-
2024
- 2024-07-29 JP JP2024122223A patent/JP2024153782A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3139925T3 (pl) | Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu | |
| HUS2100037I1 (hu) | Vegyületek gerinc eredetû izomsorvadás kezelésére | |
| IL247452A0 (en) | Compounds for treatment of complement mediated disorders | |
| IL253945B (en) | kdm1a inhibitors to treat the disease | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| GB201402070D0 (en) | Pharmaceutical compositions for the treatment of inflammatory disorders | |
| SG11201609652RA (en) | Treatment of polybacterials infections | |
| IL262852A (en) | Treatment of complement-mediated disorders | |
| HUE059303T2 (hu) | Acetilkolin-észteráz-gátlók bõrbetegségek kezelésére | |
| HUE037179T2 (hu) | Gyógyászati kompozíciók izom-rendellenességek kezelésére | |
| SG11201608729RA (en) | Membrane-adherent self-assembled systems for treatment of ocular disorders | |
| IL249502A0 (en) | Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases | |
| HUE053443T2 (hu) | Heteroaril vegyületek szembetegségek kezelésére | |
| GB201408387D0 (en) | Treatment of respiratory disorders | |
| DE112015002229A5 (de) | Formulierungen zur Behandlung von Hyperthyreose | |
| HUE070257T2 (hu) | Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére | |
| IL259381B (en) | Mirabegron for the treatment of retinal diseases | |
| GB201410407D0 (en) | Treatment of chagas disease | |
| KR101583452B9 (ko) | 위장질환 치료용 의약 조성물 | |
| PL3164110T3 (pl) | Kompozycje farmaceutyczne do leczenia łuszczycy | |
| HUE049392T2 (hu) | Paroxizmális súlyos fájdalom kezelése | |
| ES1113580Y (es) | Dispositivo dental para el tratamiento de la onicofagia | |
| GB201621398D0 (en) | Treatment of emt-associated disease | |
| GB201504413D0 (en) | Treatment of disease | |
| GB201602784D0 (en) | New treatment of CFTR-related disorders |